Enanta Pharmaceuticals | ENTA - Ordinary Share Capital


Enanta Pharmaceuticals reported $212K in Ordinary Share Capital for its fiscal quarter ending in December of 2023.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 539M 1000K Dec/2025
Anika Therapeutics USD 143K 1000 Mar/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
AstraZeneca USD 1.55B 206K Dec/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Halozyme Therapeutics USD 117.78M 259K Dec/2025
Heron Therapeutics USD 1.52M 14K Sep/2024
Immunic USD 8K 4K Jun/2024
Incyte USD 198.46M 2.33M Dec/2025
Insmed USD 214.26M 1.67M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
J&J USD 2.41B 584K Sep/2025
Karyopharm Therapeutics USD 13K 0 Sep/2024
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.94B 23.4M Jun/2025
Novavax USD 1.62M 211K Sep/2024
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025